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Abstract
Background: DNA damage such as double-stranded DNA breaks (DSBs) has been reported to stimulate mitochondrial
biogenesis. However, the underlying mechanism is poorly understood. The major player in response to DSBs is ATM (ataxia
telangiectasia mutated). Upon sensing DSBs, ATM is activated through autophosphorylation and phosphorylates a number
of substrates for DNA repair, cell cycle regulation and apoptosis. ATM has been reported to phosphorylate the a subunit of
AMP-activated protein kinase (AMPK), which senses AMP/ATP ratio in cells, and can be activated by upstream kinases. Here
we provide evidence for a novel role of ATM in mitochondrial biogenesis through AMPK activation in response to
etoposide-induced DNA damage.
Methodology/Principal Findings: Three pairs of human ATM+ and ATM- cells were employed. Cells treated with etoposide
exhibited an ATM-dependent increase in mitochondrial mass as measured by 10-N-Nonyl-Acridine Orange and MitoTracker
Green FM staining, as well as an increase in mitochondrial DNA content. In addition, the expression of several known
mitochondrial biogenesis regulators such as the major mitochondrial transcription factor NRF-1, PGC-1a and TFAM was also
elevated in response to etoposide treatment as monitored by RT-PCR. Three pieces of evidence suggest that etoposide-
induced mitochondrial biogenesis is due to ATM-dependent activation of AMPK. First, etoposide induced ATM-dependent
phosphorylation of AMPK a subunit at Thr172, indicative of AMPK activation. Second, inhibition of AMPK blocked
etoposide-induced mitochondrial biogenesis. Third, activation of AMPK by AICAR (an AMP analogue) stimulated
mitochondrial biogenesis in an ATM-dependent manner, suggesting that ATM may be an upstream kinase of AMPK in the
mitochondrial biogenesis pathway.
Conclusions/Significance: These results suggest that activation of ATM by etoposide can lead to mitochondrial biogenesis
through AMPK activation. We propose that ATM-dependent mitochondrial biogenesis may play a role in DNA damage
response and ROS regulation, and that defect in ATM-dependent mitochondrial biogenesis could contribute to the
manifestations of A-T disease.
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Introduction
MitochondriaplayimportantrolesinATPsynthesisandapoptosis
[1–4]. A number of human diseases are linked to mutations of the
mitochondrial genome [1–4]. Among these are premature ageing,
cancer, diabetes mellitus, and a variety of syndromes involving the
muscles and the central nervous system [1–4].
Humancellscontainafewhundred to thousandmitochondriaper
cell, and each mitochondrion has 1–10 copies of the 16 kb double-
stranded circular DNA that encodes 37 genes. Mitochondrial
biogenesis involves mitochondrial DNA (mtDNA) replication and
mitochondrial mass increase. Due to limited coding capacity of
mtDNA, mitochondria rely largely on nuclear genes (over 1000
genes) for their proliferation [5]. Mitochondrial biogenesis therefore
requires complex coordination between the nuclear and mitochon-
drial genomes. This is largely achieved through the peroxisome
proliferation activator receptorgamma-coactivator1a(PGC-1a)[6 ].
PGC-1a upregulates two nuclear transcription factors known as
NRF-1 and -2 (nuclear respiratory factors 1 and 2) which activate
transcription of nuclear-encoded mitochondrial genes [6–8]. PGC-
1a also upregulates mitochondrial transcription factor A, TFAM,
which stimulates transcription of mitochondrial genes [6,8–10].
Mitochondrial biogenesis has been reported to be regulated by
the energy state of cells through AMP-activated protein kinase
(AMPK) [11,12]. Upon energy depletion, activated AMPK turns
off ATP-consuming processes such as synthesis of lipids,
carbohydrates, and proteins, and turns on ATP-generating
pathways including mitochondrial biogenesis [12,13]. AMPK is
allosterically stimulated by AMP and is then activated through
phosphorylation at Thr172 of the AMPK catalytic a subunit by
upstream kinase(s) such as tumor suppressor LKB1 and CaMKK
(Ca2+/calmodulin-dependent protein kinase kinase) [14–18].
PLoS ONE | www.plosone.org 1 April 2008 | Volume 3 | Issue 4 | e2009AMPK is exquisitely sensitive to AMP/ATP ratio [19] . AMPK
directly activates PGC-1a by phosphorylation at Thr177 and
Ser538 [20], and is also known to upregulate DNA binding
activity of NRF-1 [13].
Mitochondrial biogenesis has been reported to increase in
response to DNA damage [21,22]. For example, DNA topoisom-
erase II-targeting anticancer drugs (e.g. doxorubicin, mitoxantrone
and etoposide), which are known to induce DNA double-strand
breaks (DSBs), have been reported to upregulate the abundance of
mitochondria. However, the underlying mechanism is not
understood [21,22]. The major player in response to DSBs is
ATM (ataxia telangiectasia mutated), which belongs to the PIKK
(phosphoinositide 3-kinase related kinase) family of protein kinases
[23,24]. ATM has been shown to phosphorylate AMPK a subunit
in vitro [25]. In addition, phosphorylation of the AMPK a subunit
stimulated by AICAR, an AMPK activator that can be converted
to ZMP in cells to mimic AMP, has been shown to be ATM-
dependent [26]. These results point to the possibility that ATM
may regulate mitochondrial biogenesis through AMPK.
In the current study, we demonstrate that etoposide upregulates
mitochondrial biogenesis in an ATM-dependent manner. In
addition, ATM-dependent mitochondrial biogenesis is at least in
part mediated through AMPK activation.
Results
In order to confirm that DNA damage induces mitochondrial
biogenesis, we employed etoposide, a topoisomerase II poison
known to induce DSBs and activate ATM [27,28]. HeLa cells
were treated with etoposide for 16 hrs, mitochondrial DNA
content and mitochondrial mass were then determined. As shown
in Fig. 1a, etoposide induced a dose-dependent increase in the
copy number of the mitochondrial NADH dehydrogenase subunit
2 (mtND2) gene (normalized to that of the nuclear 18S rDNA) in
HeLa cells as measured by quantitative real time PCR. The
increase in mtND2 gene copy number in HeLa cells paralleled an
increase in the mitochondrial mass as evidenced by increased
fluorescence staining of cardiolipin in the inner mitochondrial
membrane using 10-N-Nonyl-Acridine Orange (NAO) (Fig. 1b).
These results suggest that both mitochondrial DNA content and
mass were increased in response to etoposide treatment. To
provide more evidence that mitochondrial biogenesis was
activated by etoposide, the steady-state mRNA levels of several
known regulators of mitochondrial biogenesis were determined. As
shown in Fig. 1c, the mRNA level of PGC-1a, the master
regulator for mitochondrial biogenesis, increased two-fold in
etoposide-treated HeLa cells compared to that in control cells
(DMSO-treated) as measured by RT-PCR. The mRNA level of
NRF-1, a transcription regulator for nuclear-encoded mitochon-
drial genes [7], was also upregulated by etoposide. TFAM, a
regulator of mitochondrial DNA replication and transcription, has
been shown to be controlled by both NRF-1 and PGC-1a [6,29].
As shown in Fig. 1c, the mRNA level of TFAM was induced to a
similar extent as that of PGC-1a. Taken together, these results
suggest that etoposide stimulates key mitochondrial transcription
regulators and induces mitochondrial biogenesis.
Figure 1. Etoposide induces mitochondrial biogenesis. HeLa cells were treated with various concentrations of etoposide for 16 hrs. mtDNA
content (a) and mitochondrial mass (b) were determined as described in the Materials and Methods. Data are presented as mean6SEM (n=3). c. The
mRNA levels of PGC1a, NRF21 and TFAM were determined by RT-PCR. b-actin was used as a control for RT-PCR. d. HeLa cells were treated with
10 mM etoposide in the presence or absence of the caspase inhibitor z-VAD-FMK (20 mM) for 16 hrs and mtDNA content was then determined.
doi:10.1371/journal.pone.0002009.g001
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[30]. To test whether the apoptotic pathway is involved, we
blocked caspase activation using a pan-caspase inhibitor z-VAD-
FMK and found that the increase in mtDNA content in etoposide-
treated cells was not significantly affected (Fig. 1d). These results
suggest that mitochondrial biogenesis induced by etoposide is not
dependent on caspase activation.
Mitochondrial biogenesis has been reported to be regulated by
AMPK [11–13,20]. To test whether AMPK is involved in
etoposide-induced mitochondrial biogenesis, the activation of
AMPK was monitored in etoposide-treated HeLa cells by
immunoblotting using anti-phospho-Thr172 AMPK antibody.
As shown in Fig. 2a, etoposide treatment activated ATM as
evidenced by ATM autophosphorylation at Ser1981, and AMPK
as evidenced by an increase in phosphorylation of AMPK a at
Thr172.
It is well known that DSBs induced by etoposide activate ATM
kinase activity [27,28]. It has also been reported that in response to
IGF-1 stimulation, purified ATM phosphorylates and activates
AMPK [25]. We therefore hypothesize that etoposide-induced
mitochondrial biogenesis is mediated through the ATM activation.
To test this hypothesis, activation of AMPK and mitochondrial
DNA content were monitored in two pairs of ATM+/ATM2 cell
lines: ATM siRNA knockdown HeLa cells and non-specific
siRNA-transfected control HeLa cells, as well as ATM cDNA-
complemented human A-T fibroblast YZ5 (ATM+) and its vector
plasmid-transfected control pEBS7 (ATM2). As shown in Fig. 2b
and 2c, as well as supplementary Figures S1 and S2, etoposide
induced an increase in AMPK a phosphorylation at Thr172 and
in mitochondrial DNA content in ATM+ but not in ATM2 cells.
Furthermore, NRF-1 mRNA induction stimulated by etoposide
was also abolished in ATM siRNA knockdown HeLa cells as
shown in Fig. 2d. These results suggest that AMPK activation,
NRF-1 upregulation and subsequent mitochondrial biogenesis in
response to etoposide treatment are dependent on ATM.
Mitochondrial biogenesis could amplify and repopulate func-
tional mitochondria, which is expected to increase both the
mitochondrial mass and the overall mitochondrial membrane
potential [31,32]. To test this idea, we measured mitochondrial
mass and membrane potential. The pair of L40 (ATM+) and L3
(ATM2) lymphoblastoid cells were employed. As shown in
supplementary Figure S3, L40 (ATM+) cells exhibited increased
mitochondrial mass as compared to L3 (ATM2) cells in response
to etoposide treatment. To measure mitochondrial membrane
potential, cells were treated with etoposide and stained with JC-1
which accumulates as aggregates in mitochondria of high
membrane potential (red, detected in FL2) and exists as monomer
in cytoplasm (green, detected in FL1) [33]. As shown in Fig. 3a, 3b
and supplementary Figure S4, with increasing etoposide concen-
trations (0, 10 and 50 mM), a cell population with high FL2
intensity (H) was increased in ATM+ cells (10.8%, 25.6% and
57.2%, respectively), while decreased in ATM- cells (16.9%,
13.3% and 7.3%, respectively). The mean intensity of FL2 in G1
population (including H), which represents normal live cells (as
shown in Fig. 3a), also increased in ATM+ cells as shown in Fig 3c.
The FL2/FL1 values (indicative of mitochondrial membrane
potential) in G1 population were thus increased in response to
etoposide treatment in an ATM-dependent manner (Fig. 3d). It
appears that etoposide induced ATM-dependent mitochondrial
biogenesis leads to an overall increase in mitochondria of good
quality in surviving cells. Our results provide a possible
explanation for recent observations that A-T lymphoblastoid cells
from patients exhibit lower mitochondrial mass staining and lower
membrane potential [34] and that cerebellum, lung, marrow and
muscle from A-T mice exhibit lower mtDNA copy number [35].
It was also noted that the G4 cell population with depolarized
mitochondria was increased in etoposide-treated ATM+ cells in a
dose-dependent manner (0.43%, 14.1% and to 14.9% in response
to 0, 10 and 50 mM etoposide, respectively) as shown in Fig. 3, and
supplementary Figure S4. However, the increase in the G4
Figure 2. Etoposide-induced mitochondrial biogenesis is ATM-dependent. a. Activation of ATM and AMPK were determined by Western
blotting using specific antibodies against phosphorylated ATM at Ser1981 and phosphorylated AMPK at Thr172. a-tubulin was used as loading
controls. HeLa cells were treated with 10 mM etoposide for 16 hrs. b–c. HeLa cells transfected with ATM siRNA or non-specific siRNA (NS siRNA) were
treated with etoposide for 16 hrs. The mtDNA content was determined by quantitative real-time PCR (b). Phosphorylated AMPK at Thr172 was
monitored by Western blotting (c). d. ATM siRNA and NS siRNA HeLa cells were treated with etoposide for 16 hrs. RNA was then isolated and the
NRF-1 mRNA level was determined using RT-PCR.
doi:10.1371/journal.pone.0002009.g002
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and 74.9% in response to 0, 10 and 50 mM etoposide, respectively)
comparing to that in ATM+ cells. MTT assay also showed that
ATM+ cells were more resistant to etoposide than ATM- cells
(Supplementary Figure S5). These results suggest that in the
absence of ATM, DSBs induced by etoposide triggers a cell death
Figure 3. ATM increases mitochondrial membrane potential in surviving population. a. L40 (ATM+) and L3 (ATM2) cells were treated with
indicated concentrations of etoposide for two days, followed by JC-1 staining and FACS analysis. Data were collected from normal living cell
population that was gated according to the controls (no treatment) based on forward and side scatterings. b–d. Results were obtained from
supplementary Fig. S4. b. Percentages of the H and the G4 populations in ATM+ and ATM2 cells were plotted against etoposide concentrations. c.
The mean intensities of FL2 in G1 population were plotted against etoposide concentrations. d. The ratios of the mean intensity of FL2 to the mean
intensity of FL1 for G1 cells (including H cells) were plotted against etoposide. Data are a representative of three independent experiments.
doi:10.1371/journal.pone.0002009.g003
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to protect cells from this cell death pathway through its role in
mitochondrial biogenesis and/or DNA repair.
To test whether AMPK plays a critical role in ATM-dependent
mitochondrial biogenesis, the AMPK specific inhibitor, compound
C, was employed [36]. Compound C was identified through a
high-throughput in vitro assay from a library containing more than
10, 000 small molecules [36]. It is a potent reversible AMPK
inhibitor that competes with ATP with Ki=109616 nM in the
absence of AMP [36]. As shown in Fig. 4a, compound C (10 mM)
blocked the increase in mitochondrial mass induced by etoposide
as measured by NAO staining of living cells. Furthermore, the
increase in H population and in the mean FL2 intensity of G1
population induced by etoposide (5 mM) were both blocked by
compound C (Fig. 4b and 4c). In order to confirm these results,
knockdown of AMPK using siRNA specifically against the AMPK
a subunit in HeLa cells was carried out. As shown in Fig. 4d and
4e, AMPK a was knocked down by the siRNA, which abolished
mitochondrial mass increase induced by etoposide at 1 and
10 mM. These results suggest that ATM regulates mitochondrial
biogenesis through AMPK, which is also responsible for the
increase in mitochondrial membrane potential of the G1
population.
The AMPK activator AICAR can be converted to ZMP in cells
to mimic AMP, and therefore creates a situation that mimics ATP
reduction or high AMP/ATP ratio in cells [37,38]. As shown in
Fig 5a, AICAR increased phosphorylation of AMPK a subunit at
Thr172 after 100 min in L40 (ATM+) cells, but not in L3
(ATM2) cells, consistent with a recent report that phosphorylation
of the AMPK a subunit at Thr172 by AICAR requires ATM in
MEF cells [26]. We further tested whether AICAR-induced
mitochondrial biogenesis was affected by ATM. As shown in
Fig. 5b, AICAR (250 mM) promoted mitochondrial mass increase
in ATM+ L40 cells, but not in ATM- L3 cells. The increases in H
population and the mean FL2 intensity of G1 population (healthy
cells) induced by AICAR were also dependent on ATM (Fig. 5c
and 5d). These results suggest that ATM is required for AICAR-
induced AMPK activation and subsequent mitochondrial biogen-
esis. These results together with the observation that ATM
phosphorylates AMPK [25], suggest that ATM could act as an
upstream kinase of AMPK in the mitochondrial biogenesis
pathway. It is possible that normal ATM activation at the end
of G2 phase [39] or by hormone (serum) stimulations [25] may be
responsible for the AICAR-induced AMPK/mitochondrial bio-
genesis. Clearly, further studies are needed to determine the
mechanism of the ATM/AMPK/mitochondrial biogenesis path-
way.
To test whether DNA damage-induced mitochondrial biogen-
esis is a general phenomenon in all cell types, post-mitotic cortical
neurons were isolated from mouse embryos (embryonic day 17.5).
Figure 4. Inhibition of AMPK abolishes etoposide-induced mitochondrial biogenesis. a. Compound C blocks etoposide-induced increase
in mitochondrial mass. L40 (ATM+) cells were treated with DMSO (control), 5 mM etoposide, 10 mM compound C, and 5 mM etoposide plus 10 mM
compound C for 18 hrs. Cells were then stained by 1 mM NAO for FACS analysis. Data were obtained from three independent experiments. b–c.
Compound C inhibits the increase in FL2 intensity of survival cells, as well as the increase of the H cell population. L40 (ATM+) cells were treated as
described in a. Cells were then stained with JC-1 prior to FACS analysis. d. HeLa cells were transfected with siRNA against AMPK a or non-specific
siRNA (NS). Knockdown of AMPK a was monitored by Western blotting using an antibody against AMPK a. e. AMPK a siRNA inhibits the increase in
mitochondrial mass induced by etoposide. Cells were treated with indicated concentrations of etoposide (VP16) for 18 hrs. Cells were fixed by 60%
ethanol and stained with MitoTracker Green FM prior to FACS analysis. 10,000 cells were analyzed.
doi:10.1371/journal.pone.0002009.g004
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mitochondrial DNA content in mouse cortical neurons. Since
defects in activation of mitochondrial biogenesis and regulation of
mitochondrial dynamics have been demonstrated to play impor-
tant roles in neuronal degeneration [40–42], it is possible that the
lack of mitochondrial biogenesis in response to DNA damage also
contributes to the neuronal degeneration in A-T patients.
It has been shown that H2O2 can activate mitochondrial
biogenesis [43]. To test whether this might also be through the
ATM/APMK pathway, we monitored activation of ATM and
AMPK. As shown in Fig. 7, H2O2 treatment activated ATM as
evidenced by ATM autophosphorylation at Ser1981 and Ser15
phosphorylation of p53 (a substrate of ATM). H2O2 treatment also
activated AMPK as evidenced by Thr172 phosphorylation of
AMPK a and Ser79 phosphorylation of ACC (Acetyl-CoA
Carboxylase, a substrate of activated AMPK). These results
suggest that ROS might promote mitochondrial biogenesis
through the DNA damage/ATM/AMPK pathway.
Discussions
Previous studies have demonstrated that DNA damaging agents
such as etoposide and doxorubicin induce mitochondrial biogen-
esis [21,22]. In the current study, we show that etoposide-induced
mitochondrial biogenesis is ATM-dependent as evidenced in three
pairs of ATM-deficient cells. We have also provided evidence that
ATM-dependent mitochondrial biogenesis is mediated through
AMPK, an energy sensor known to be exquisitely sensitive to
AMP/ATP ratio [19]. It has been reported that etoposide induces
Figure 5. AICAR induces ATM-dependent mitochondrial biogenesis. a. Cells were treated with 250 mM AICAR for 100 min. Their lysates were
then analyzed for activation of AMPK by using an antibody against phosphorylated AMPK a at Thr172. b. AICAR increases mitochondrial mass in
ATM+, but not ATM2 cells. Cells were treated with 250 mM AICAR for 2 days. They were then fixed and stained by 50 mM Mitotracker Green FM
followed by FACS analysis. c–d. AICAR induces ATM-dependent increase in mitochondrial membrane potential. Cells were treated with 250 mM
AICAR for 2 days, and then stained with JC-1, followed by FACS analysis.
doi:10.1371/journal.pone.0002009.g005
Figure 6. Etoposide increases mitochondrial DNA content in
mouse cortical neurons. Isolated embryonic mouse cortical neurons
(embryonic day 17.5) were treated with etoposide for 18 hrs. The
relative amount of the mitochondrial mtND2 gene in mouse cortical
neurons was measured by quantitative real-time PCR.
doi:10.1371/journal.pone.0002009.g006
Figure 7. H2O2 treatment increases ATM autophosphorylation,
and phosphorylations of p53, AMPK a and ACC (Acetyl-CoA
Carboxylase). HeLa cells were treated with indicated concentrations
of H2O2 for 16 hrs followed by cell lysis. Western blottings were
performed using antibodies against phosphorylated ATM (Ser1981),
p53 (Ser15), AMPK a (Thr172) and ACC (Ser79), respectively.
doi:10.1371/journal.pone.0002009.g007
ATM and Mitochondria
PLoS ONE | www.plosone.org 6 April 2008 | Volume 3 | Issue 4 | e2009a drop in ATP pool [44]. This is further supported by the
observation in bacteria that DNA damage induces a RecA-
dependent drop in the ATP pool [45,46]. It has also been
demonstrated that ATM positively regulates the ATP pool since
the ATP pool is significantly lower in A-T cells compared to
ATM+ cells [47]. On the other hand, it has been demonstrated
that ATM phosphorylates AMPK in vitro and activates AMPK
through Thr172 phosphorylation in vivo [25,26]. We have also
shown that AICAR, which generates an ATP-deficient condition
in cells, also requires ATM for mitochondrial biogenesis. It is likely
that DNA damage induced activation of AMPK and subsequent
mitochondrial biogenesis may be mediated through both the
AMP/ATP ratio change and ATM activity (a proposed AMPK
upstream kinase).
Mutation in ATM leads to the human disease ataxia-telangiectasia
(A-T). The major clinical manifestation of A-T is ataxia, which is
due to progressive cortical cerebellar degeneration primarily in
Purkinje and granular cells [48–51]. In addition, A-T patients are
immunodeficient and predisposed to cancers, particularly lym-
phomas and leukemia [52–58]. Furthermore, individuals with A–
T exhibit premature aging, including elevated diabetes mellitus
incidence and progeric hair and skin changes [48,59–62]. This
disease also manifests sensitivity to ionizing radiation [63–65].
ATM is known to be a key sensor for DNA double-strand
breaks (DSBs) and is activated through autophosphorylation
[23,24,66]. Upon activation, ATM phosphorylates a number of
substrates for DNA repair, cell cycle regulation and apoptosis [67–
69]. Growing evidence has suggested that ATM plays an
important role in oxidative stress [70]. Individuals with A–T
exhibit elevated oxidative stress as compared to normal controls,
including increased oxidative damage to DNA and lipids, and
antioxidant defense alterations secondary to oxidative stress
[71,72]. ATM-deficient mice similarly exhibit elevated oxidative
stress [73–77]. Interestingly, administration of antioxidant (e.g.
EUK-189 and NAC) to ATM-deficient mice lowers oxidative
DNA, lipid, and protein damages, reduces cancer incidences,
inhibits cerebellar Purkinje cell death, and partially reverses the
neurological deficits and premature aging seen in these mice
[73,78–81]. However, the molecular basis for increased ROS in A-
T cells is still unclear.
ROS is known to be primarily produced in mitochondria due to
incomplete reduction of oxygen during oxidative phosphorylation
for ATP production. Defects in mitochondrial function such as
inefficient oxidative phosphorylation and loss of membrane
potential can lead to elevated ROS production. Mitochondrial
quality is maintained through biogenesis of functional mitochon-
dria, as well as turnover of defective mitochondria [82]. We have
shown that ROS (H2O2) can activate ATM and AMPK (Fig. 7). It
has also been reported that H2O2 increases mitochondrial
biogenesis [43]. These results suggest that ROS might increase
mitochondrial biogenesis through a DNA damage/ATM/AMPK
pathway. We therefore propose that ROS may perturb mito-
chondrial homeostasis through two opposing effects. First, ROS
can damage mitochondria leading to the production of more ROS
and more defective mitochondria via a vicious cycle. Second, ROS
can also induce mitochondrial biogenesis through a DNA
damage/ATM/AMPK pathway and therefore ameliorate the
ROS-mediated vicious cycle. In A-T cells, the lack of ATM/
AMPK/mitochondrial biogenesis leads to elevated production of
ROS due to the unchecked vicious cycle. The elevated ROS will
result in more DNA damage (in both mitochondrion and nucleus),
and eventually depolarization of mitochondria (as seen in Fig. 3a)
and cell death. The fact that ATM deficient cells are also defective
in DNA damage repair could worsen the situation.
Based on this view, mitochondrial biogenesis may be critical for
controlling ROS production and ROS-mediated DNA damage. It
is possible that defect in ATM/AMPK/mitochondrial biogenesis
in A-T patients may contribute significantly to some of the A-T
manifestations which can be reversed by antioxidants. Cerebellar
Purkinje cell death and neurological deficits in A-T mice have
been shown to be inhibited by antioxidants [60,78]. We have
shown (Fig. 6) that DNA damage induced by etoposide treatment
stimulates mitochondrial biogenesis in mouse neuronal cells. It is
tempting to speculate that lack of the ATM/AMPK/mitochon-
drial biogenesis pathway may be a major cause for the progressive
cerebellar degeneration in A-T patients. Interestingly, defects in
mitochondria and mitochondrial biogenesis have been linked to
neurodegenerative diseases, diabetes mellitus and other aging
diseases [1–4,40–42]. Furthermore, antioxidants have also been
shown to suppress cancer incidences, inhibit immunodeficiency
and extend lifespan in A-T mice, in addition to neurological
deficits [73,78–81]. It is possible that defect in mitochondrial
biogenesis plays an important role in ROS regulation and the
development of A-T disease. Thus, mitochondrial biogenesis can
be targeted for its therapy.
It has been reported that ATM can also be activated by certain
dietary components (e.g. resveratrol in red wine, benzyl isothio-
cyanate (BITC) in papaya and certain vegetables and the
micronutrient selenium) [83–85] that are known to have anti-
aging or anticancer activities. It is tempting to speculate that these
dietary components may stimulate mitochondrial biogenesis
through ATM to maintain functional mitochondria and regulate
ROS. Clearly, more studies are needed to establish the role of
ATM-dependent mitochondrial biogenesis in dietary modulation
of cancer and aging.
Materials and Methods
Reagents
Etoposide (VP16) was purchased from Sigma-Aldrich (St. Louis,
MO). The fluorescent dyes 10-n-Nonyl-Acridine Orange (NAO),
MitoTracker Green FM, and 5,59,6,69-tetrachloro-1,19,3,39-tetra-
ethylbenzimidazole carbocyanide iodide (JC-1) were purchased
from Invitrogen (Carlsbad, CA). Caspase inhibitor z-VAD-FMK
was purchased from Promega (Madison WI). The primer and
probe set for detecting human mitochondrial NADH dehydroge-
nase subunit 2 (mtND2) and the endogenous control for detecting
18S rDNA were purchased from Applied Biosystems (Foster City,
CA). Antibodies against AMPK a and phosphorylated ATM at
Ser1981, p53 at Ser15, AMPK at Thr172 and ACC at Ser79 were
purchased from Cell Signaling (Danvers, MA). Monoclonal
antibody against a-tubulin was obtained from Sigma-Aldrich.
Compound C was a kind gift from Dr. Gaoqiao Zhou (Merck
Research Laboratories, Rahway, NJ). siRNA against AMPK a1
subunit (sc-29673) was purchased from Santa Cruz Biotechnology,
Inc (Santa Cruz, CA).
Cell Culture
HeLa cells were purchased from American Type Culture
Collection (Manassas, VA), and were cultured in complete
DMEM (DMEM supplemented with 10% FCS, 100 units/ml
penicillin, 100 mg/ml streptomycin and 2 mM glutamine). The
transformed FT169A A-T fibroblasts stably transfected with
plasmid vector pEB7 (ATM2) and the ATM cDNA YZ5
(ATM+) (obtained from Dr. Y. Shiloh, Tel Aviv University, Israel)
[86] were cultured in complete DMEM supplemented with
100 mg/ml hygromycin. The HeLa ATM601 (ATM siRNA) and
its control NS siRNA (Non Specific siRNA) cell lines (obtained
ATM and Mitochondria
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were cultured in complete DMEM supplemented with 400 mg/ml
G418. Lymphoblastoid L40 (ATM+) and L3 (ATM2) (obtained
from Dr. Yosef Shiloh) [88] were cultured in RPMI medium
supplemented with 10% FCS, 100 units/ml penicillin, 100 mg/ml
streptomycin and 2 mM glutamine. Mouse cortical neurons were
cultured in neurobasal medium (NBM, Invitrogen, Carlsbad, CA)
supplemented with B27 (Invitrogen, Carlsbad, CA), 0.5 mM
Glutamine, 100 units/ml penicillin and 100 mg/ml streptomycin.
All cells were cultured in a humidified atmosphere consisting of
95% air and 5% CO2.
Measurement of Mitochondrial DNA Content
Cells were seeded at a density of 50,000 cells per dish in 35 mm
dishes one day prior to drug treatment. Etoposide treatment usually
lasts for 16 hrs unless indicated otherwise. After the treatment, cells
were washed twice with Phosphate Buffered Saline (PBS, pH 7.2)
and lysed in 100 ml lysis buffer (1 mM EDTA, 10 mM Tris, pH
8.0, 1% SDS). Cell lysates were then denatured at 95uC for 20 min
and diluted 25-folds with water. Four microliters of the diluted cell
lysates were used for the quantitative real time PCR reaction.
Mitochondrial DNA was quantified using a probe that specifically
recognizes the mitochondrial gene MtND2. The mouse mtND2
primer set and probe were designed using Primer Express software
and synthesized by Applied Biosystems (Foster City, CA). The




The amount of 18S rDNA in the same reaction was
simultaneously determined and used as the internal control. The
quantitative real time PCR reaction was carried out in a total
volume of 20 ml using TaqMan reagents following the manufac-
turer’s instructions (Applied Biosystem, TaqMan Universal PCR
Master Mix). Sequence-specific amplification was detected on the
ABI Prism 7900 sequence detection system (Applied Biosystems).
Data were extracted and analyzed using the SDS2.1 software
(Applied Biosystem).
Determination of Mitochondrial Mass
NAO-staining. The fluorescent dye 10-N-Nonyl-Acridine
Orange (NAO) binds specifically to cardiolipin at the inner
mitochondrial membrane independently of membrane potential
and was used to monitor the mitochondrial mass as described
before [22]. Once treatment was completed, cells were trypsinized
and stained with 1 mM NAO at room temperature in the dark for
10 min, followed by FACS analysis. The mean fluorescence
intensity was plotted against each treatment. Mitochondrial mass
was also measured by Mitotracker Green FM staining.
Treated cells were fixed by 60% ethanol at 4uC. After washing
with PBS, fixed cells were stained by 50 mM Mitotracker Green
FM followed by FACS analysis.
RT-PCR
Total RNA was isolated using Trizol reagent (Invitrogen) and
cleaned with the RNeasy Mini Kit (Qiagen) according to the
manufacturer’s instructions. About 1–2 mg RNA was used for the
synthesis of first strand cDNA using the SuperScript III First-Strand
Synthesis System (Invitrogen). PCR reaction was performed on a
PTC-100 Thermal Cycler (MJ Research) and PCR products were
analyzed by electrophoresis on a 2% agarose gel. The images of
ethidium bromide-stained agarose gels were captured on the Kodak
Image Station 2000R. The band intensity of PCR products were
quantified using the KODAK 1D 3.6 software.
The specific primers used are as follows: 59-TGGGACAG-
CAAGCTATTGTCCTCT-39, NRF-1 forward primer. 59-ACTG-
GAATTCCGTCGATGGTGAGA-39, NRF-1 reverse primer. 59-
ACCTGACACAACACGGACAGAACT-39,P G C - 1 a forward
primer. 59-TCTTGGTGGAAGCAGGGTCAAAGT-39,P G C - 1 a
reverse primer. 59-ACAGCTAACTCCAAGTCAGATTATGTC-
39,T F A Mf o r w a r dp r i m e r .5 9-GTAGACACTTGAGACTAACA-
ACCGT-39, TFAM reverse primer. 59CAAAGACCTGTACGC-
CAACACAGT39, b-Actin forward primer. 59-TTGCTGATCCA-
CATCTGCTGGAAG-39, b-Actin reverse primer.
Determination of Mitochondrial Membrane Potential
JC-1 was added to treated cells to a final concentration of
2.5 mg/ml. Cells were stained in the dark at 37uC for 15 min.
They were then washed with PBS once, followed by FACS
analysis. Photomultiplier settings were adjusted to detect green
fluorescence (lem=525 nm) of JC-1 monomer using filter 1 (FL1
detector) and the red fluorescence (lem=590 nm) of JC-1
aggregates using filter 2 (FL2 detector). In each experiment, at
least 10,000 events were analyzed. Data were collected from
normal cell population for each sample, which was gated
according to the no treatment controls based on forward and
side scatters. The ratios of JC-1 aggregate/monomer (red/green or
FL2/FL1) reflect mitochondrial membrane potential.
Isolation of Mouse Cortical Neurons
All mice were maintained in accordance with the guidelines of the
Institutional Animal Care and Use Committee (IACUC) at
University of Medicine and Dentistry at New Jersey (UMDNJ)-
Robert Wood Johnson Medical School. Mouse cortical neurons
were isolated from E17.5 C57/BL6 mouse embryos (embryonic day
17.5) as described [89]. Briefly, cerebral cortex was removed from
mouse embryos and the surrounding meninges/blood vessels were
peeled off to minimize contamination from endothelial cells. The
braintissuewasmincedanddigestedwithtrypsin.Thetrypsinization
reaction wasstopped withsoybeantrypsin inhibitorand the mixtures
were digested with DNase I. The remaining tissue was triturated
gentlythroughafire-polishedPasteurpipetteandcellswerecollected
from the resulting homogeneous suspension by centrifugation. The
isolated mouse cortical neurons were then plated on Poly-L-lysine
(PLL)-coated tissue culture plates and allowed to recover for 48 hrs
prior to various treatments.
MTT assay
About 3000 cells per well (YZ5 or pEBS7) were seeded in 96-
well plates and cultured overnight for re-attachment. Cells were
then treated with indicated concentrations of etoposide for 18 hrs
followed by 3-day culture in fresh medium. MTT assay was
performed as described in [90]. In brief, cells were stained with
0.1 mg/ml MTT (Sigma) for 4 hrs and then dissolved in DMSO.
MTT values were measured at 570 nm by a Biorad 3550
microplate reader.
Supporting Information
Figure S1 Activation of AMPK by etoposide is ATM-depen-
dent. YZ5 cells (A-T cells stably transfected with the ATM cDNA
expression plasmid) and pEBS7 cells (A-T cells stably transfected
with the vector) were treated with indicated concentrations of
etoposide for 16 hrs and activation of AMPK was monitored using
an antibody specific to phosphorylated AMPK a at Thr-172.
Found at: doi:10.1371/journal.pone.0002009.s001 (4.01 MB TIF)
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PLoS ONE | www.plosone.org 8 April 2008 | Volume 3 | Issue 4 | e2009Figure S2 Etoposide-induced increase in mitochondrial DNA
content is ATM-dependent. ATM- cells (AT cells stably
transfected with the vector, pEBS7) and ATM+ cells (AT cells
stably transfected with the ATM cDNA expression plasmid, YZ5)
were treated with indicated concentrations of etoposide and the
amounts of the mitochondrial mtND2 gene were determined by
quantitative real time PCR.
Found at: doi:10.1371/journal.pone.0002009.s002 (1.76 MB TIF)
Figure S3 Etoposide-induced increase in mitochondrial mass is
ATM-dependent. L3 (ATM2) and L40 (ATM+) lymphoblastoid
cells were treated with etoposide for 2 days and fixed with 60%
ethanol. Mitochondrial mass was determined by MitoTracker
Green FM staining and FACS analysis.
Found at: doi:10.1371/journal.pone.0002009.s003 (5.04 MB
DOC)
Figure S4 ATM improves mitochondrial membrane potential in
surviving cells. L3 (ATM2) and L40 (ATM+) cells were treated
with indicated concentrations of etoposide for two days, followed
by JC-1 staining and FACS analysis.
Found at: doi:10.1371/journal.pone.0002009.s004 (10.31 MB
TIF)
Figure S5 ATM+ cells are more resistant to etoposide than
ATM2 cells. L40 (ATM+) and L3 (ATM2) cells were treated
with etoposide for 18 hrs. Cells were then replenished with fresh
medium and incubated for additional 3 days before MTT assay
was performed. For MTT assay, cells were stained with 0.1 mg/
ml MTT (Sigma) for 4 hrs and then dissolved in DMSO. MTT
values were measured at 570 nm by a Biorad 3550 microplate
reader.
Found at: doi:10.1371/journal.pone.0002009.s005 (2.42 MB TIF)
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